Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution-Reference-Cited by-同舟云学术

Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution

Published:2016-12-01 Issue:3 Volume:8 Page:4156-4168
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

He Jin-Xue¹,Wang Meng²,Huan Xia-Juan¹,Chen Chuan-Huizi¹,Song Shan-Shan¹,Wang Ying-Qing¹,Liao Xue-Mei¹,Tan Cun²,He Qian²,Tong Lin-Jiang¹,Wang Yu-Ting¹,Li Xiao-Hua¹,Su Yi¹,Shen Yan-Yan¹,Sun Yi-Ming¹,Yang Xin-Ying¹,Chen Yi¹,Gao Zhi-Wei³,Chen Xiao-Yan³,Xiong Bing²,Lu Xiu-Lian⁴,Ding Jian¹,Yang Chun-Hao²,Miao Ze-Hong¹

Affiliation:

1. Division of Anti-Tumor Pharmacology and State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China, University of Chinese Academy of Sciences, Beijing 100049, China

2. Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China, University of Chinese Academy of Sciences, Beijing 100049, China

3. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

4. Cisen Pharmaceutical Co., LTD, Jining 272073, Shandong, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. De novo design of drug-binding proteins with predictable binding energy and specificity;Science;2024-04-05

2. De novodesign of drug-binding proteins with predictable binding energy and specificity;2023-12-23

3. Cell membrane-coated mesoporous silica nanorods overcome sequential drug delivery barriers against colorectal cancer;Chinese Chemical Letters;2023-06

4. Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance;EMBO Molecular Medicine;2023-01-18

5. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials;Oncology Research;2023